STOCK TITAN

Precigen Stock Price, News & Analysis

PGEN NASDAQ

Company Description

Overview of Precigen Inc (PGEN)

Precigen Inc is a clinical stage biopharmaceutical company that develops and refines innovative gene and cell therapies using cutting-edge synthetic biology and precision technology. With proprietary platforms such as UltraCAR-T and AdenoVerse, the company designs, builds, and regulates complex gene expression programs to address intractable diseases. Its expertise in non-viral gene transfer methods and advanced DNA construction techniques positions the company as a significant innovator across multiple therapeutic areas including immuno-oncology, autoimmune disorders, and infectious diseases.

Core Business and Technological Platforms

Precigen leverages a comprehensive suite of technologies to discover and develop next generation therapeutics. The company utilizes an advanced UltraVector platform for DNA construction, facilitating the design and assembly of gene components. Its UltraCAR-T platform, which employs a non-viral Sleeping Beauty system, enables the rapid manufacturing of personalized cell therapies with an improved safety profile and simplified logistics. Additionally, the AdenoVerse platform uses a library of engineered adenovector serotypes that efficiently deliver gene therapies aimed at modulating immune responses.

Business Model and Collaborations

The business model of Precigen is centered on leveraging its proprietary technology platforms through strategic collaborations with industry experts who bring extensive development, manufacturing, and commercial capabilities. These partnerships generate revenue primarily via technology access fees, milestone payments, royalties, and reimbursement of collaborative costs. This model provides a stable framework for continuous innovation and the effective translation of preclinical discoveries into viable clinical therapies.

Market Position and Competitive Landscape

In the competitive biotechnology arena, Precigen distinguishes itself through its robust research capabilities and a diversified portfolio of therapeutic candidates. Its unique non-viral gene transfer methods and rapid manufacturing techniques set it apart from traditional gene and cell therapy developers. By focusing resources on technologies with high clinical and commercial potential, the company addresses critical unmet needs in the therapeutic landscape, thereby reinforcing its market significance.

Operational Focus and Expertise

Precigen’s operations are built on years of scientific expertise in genetic engineering and computational model integration for therapeutic design. The company’s detailed approach to tailoring gene expression programs allows for improved functional characteristics of immune cells and precise control over therapeutic outcomes. Its methodical approach and dedication to iterative clinical development underscore its commitment to advancing medicine with precision.

Summary of Value Proposition

Precigen excels in translating complex genetic information into transformative therapies with the potential to modify the disease course in challenging therapeutic areas. By continually streamlining its research and operational models, the company ensures that its innovative techniques remain at the forefront of scientific excellence and commercial relevance. The integrated approach of technology, clinical expertise, and strategic partnerships makes Precigen a notable entity within the biopharmaceutical industry.

Stock Performance

$1.73
+3.59%
+0.06
Last updated: August 3, 2025 at 19:59
2.24 %
Performance 1 year
$510.7M
Market Cap
295.2M
Shares outstanding

Financial Highlights

-$126,235,000
Net Income (TTM)
-$0.47
Diluted EPS (TTM)
-$68,173,000
Operating Cash Flow
4.76
Current Ratio
Revenue (TTM)
Net Profit Margin

Upcoming Events

August 27, 2025
PDUFA target action date
August 27, 2025
PRGN-2012 FDA decision
August 27, 2025
PRGN-2012 PDUFA date
FDA decision on PRGN-2012 BLA under priority review

Frequently Asked Questions

What is the current stock price of Precigen (PGEN)?

The current stock price of Precigen (PGEN) is $1.67 as of August 1, 2025.

What is the market cap of Precigen (PGEN)?

The market cap of Precigen (PGEN) is approximately 510.7M.

What is the net income of Precigen (PGEN)?

The trailing twelve months (TTM) net income of Precigen (PGEN) is -$126,235,000.

What is the earnings per share (EPS) of Precigen (PGEN)?

The diluted earnings per share (EPS) of Precigen (PGEN) is -$0.47 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Precigen (PGEN)?

The operating cash flow of Precigen (PGEN) is -$68,173,000.

What is the current ratio of Precigen (PGEN)?

The current ratio of Precigen (PGEN) is 4.76, indicating the company's ability to pay short-term obligations.

What is the primary focus of Precigen Inc?

Precigen Inc specializes in the discovery and development of innovative gene and cell therapies using precision synthetic biology techniques.

How does Precigen generate revenue?

The company generates revenue through strategic collaborations that involve technology access fees, milestone payments, royalties, and reimbursement of development costs.

What distinguishes Precigen's technological platforms?

Precigen is recognized for its proprietary platforms, including UltraCAR-T and AdenoVerse, which employ non-viral gene transfer and advanced DNA construction methods to create effective therapeutic solutions.

Which therapeutic areas does Precigen target?

The company focuses on addressing critical diseases in immuno-oncology, autoimmune disorders, and infectious diseases, among other high-need medical conditions.

How is Precigen positioned in the competitive biotechnology landscape?

Precigen differentiates itself with its advanced non-viral gene transfer technology and rapid manufacturing processes, enabling the development of highly specialized therapies that tackle unmet medical needs.

What role do partnerships play in Precigen's business model?

Partnerships are central to Precigen's business model, providing access to additional resources and expertise in areas such as clinical development, manufacturing, and commercialization to accelerate the translation of its therapies.